First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients

Background: YYB101, a humanized monoclonal antibody against hepatocyte growth factor (HGF), has shown safety and efficacy in vitro and in vivo . This is a first-in-human trial of this antibody. Materials and Methods: YYB101 was administered intravenously to refractory cancer patients once every 4 we...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Seung Tae Kim, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Whan Park, Neunggyu Park, Hukeun Lee, Sung Hee Hong, Song-Jae Lee, Seong-Won Song, Kyung Kim, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Do-Hyun Nam, Jeong-Won Lee, Keunchil Park, Kyoung-Mee Kim, Jeeyun Lee
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publishing 2020-06-01
Serija:Therapeutic Advances in Medical Oncology
Online pristup:https://doi.org/10.1177/1758835920926796
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items